Medicare Part B Prior Authorization
Part B Prior Authorization Criteria for Approval
The requested Part B medication will be approved when BOTH of the following are met:
- ONE of the following:
- There is an applicable national coverage determination (NCD) or local coverage determination (LCD) from the Medicare Administrative Contractor (MAC) for the jurisdiction and the patient meets all of the requirements listed within the NCD or LCD OR
- There is NOT an applicable NCD or LCD and the requested medication is being used according to FDA labeling or in accordance with a CMS supported compendia (i.e., NCCN, Clinical Pharmacology, Lexicomp Lexi-Drugs, Merative Micromedex, & AHFS-DI) or published peer-reviewed literature AND
- ONE of the following:
- The requested medication is being evaluated for approval for the first time OR
- The request is for continuation of therapy and the patient has shown beneficial response to therapy
Length of Approval: See Table 1 below
NOTES:
- Length of approval may be shorter due to provider network participation status.
Table 1: Part B Prior Authorization
Bevacizumab (Oncology)
HCPCS | Medication | Length of Approval | NCD/LCD |
---|---|---|---|
Q5107 | Mvasi | 12 months | N/A |
Q5118 | Zirabev | 12 months | N/A |
Trastuzumab
HCPCS | Medication | Length of Approval | NCD/LCD |
---|---|---|---|
Q5117 | Kanjinti | 12 months | N/A |
Q5116 | Trazimera | 12 months | N/A |
Rituximab
HCPCS | Medication | Length of Approval | NCD/LCD |
---|---|---|---|
Q5119 | Ruxience | 12 months | L35026 |
Q5115 | Truxima | 12 months | L35026 |
Long-Acting Colony Stimulating Factors
HCPCS | Medication | Length of Approval | NCD/LCD |
---|---|---|---|
Q5108 | Fulphila | 12 months | L37176 |
Q5122 | Nyvepria | 12 months | L37176 |
Short-Acting Colony Stimulating Factors
HCPCS | Medication | Length of Approval | NCD/LCD |
---|---|---|---|
J2820 | Leukine | 12 months | L37176 |
Q5110 | Nivestym | 12 months | L37176 |
Q5101 | Zarxio | 12 months | L37176 |
Immune Globulins
HCPCS | Medication | Length of Approval | NCD/LCD |
---|---|---|---|
J1551 | Cutaquig (SC) | 12 months | L33794 |
J1569 | Gammagard Liquid (IV or SC) | 12 months | L34580 L33794 |
J1566 | Gammagard S/D (IV) | 12 months | L34580 |
J1561 | Gammaked (IV or SC) | 12 months | L34580 L33794 |
J1561 | Gamunex-C (IV or SC) | 12 months | L34580 L33794 |
J1559 | Hizentra (SC) | 12 months | L33794 |
J1575 | HyQvia (SC) | 12 months | L33794 |
J1599 | Immune Globulin, intravenous, not otherwise specified | 12 months | L34580 |
J1568 | Octagam (IV) | 12 months | L34580 |
J1459 | Privigen (IV) | 12 months | L34580 |
J1558 | Xembify (SC) | 12 months | L33794 |
Infliximab
HCPCS | Medication | Length of Approval | NCD/LCD |
---|---|---|---|
Q5121 | Avsola | 12 months | L35677 |
Q5103 | Inflectra | 12 months | L35677 |
Miscellaneous
HCPCS | Medication | Length of Approval | NCD/LCD |
---|---|---|---|
J3490 | Empaveli | 12 months | N/A |
J3590 C9399 | Enspryng | 12 months | N/A |
J2507 | Krystexxa | 12 months | N/A |
J0896 | Reblozyl | 12 months | N/A |
J9333 | Rystiggo | 12 months | N/A |
G2082 G2083 | Spravato | 6 months | N/A |
J3241 | Tepezza | 6 months | N/A |
J1303 | Ultomiris | 12 months | N/A |
J1823 | Uplizna | 12 months | N/A |
J9332 | Vyvgart | 12 months | N/A |
J9334 | Vyvgart Hytrulo | 12 months | N/A |
*See separate medical drug policies for the following drugs: Amvuttra, Onpattro and Oxlumo.
Revision History
12/11/2024:
- Trastuzumab
- Removed HCPCS code Q5114 for Ogivri
- Added HCPCS code Q5116 for Trazimera
- Long-Acting Colony Stimulating Factors
- Added HCPCS code Q5108 for Fulphila
- Added HCPCS code Q5122 for Nyvepria
- Removed HCPCS code Q5111 for Udenyca, Udenyca Onbody
- Removed HCPCS code Q5120 for Ziextenzo
- Immune Globulins
- Removed HCPCS code J1599 for Alyglo
- Removed HCPCS code J1554 for Asceniv
- Removed HCPCS code J1556 for Bivigam
- Removed HCPCS code J1555 for Cuvitru
- Removed HCPCS code J1572 for Flebogamma
- Removed HCPCS code J1557 for Gammaplex
- Removed HCPCS code J1576 for Panzyga
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2025 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.